Onconetix IncOnconetix provides up to $5M bridge financing to its acquisition target Realbotix, with the advance reducing cash needed at closing.

Onconetix, Inc. has provided a strategic bridge financing facility of up to $5,000,000 to Realbotix LLC, the target of its pending acquisition, with an initial advance of $2,500,000. The facility is non-interest bearing prior to closing of the Share Exchange Agreement between the two companies announced on February 12, 2026, and upon closing the facility and all obligations under it will be automatically cancelled and discharged in full. The cash required at closing will be reduced by the total principal advanced under the facility plus an additional $500,000, and if the Share Exchange Agreement is terminated, interest accrues at 12% per annum from the date of termination. Onconetix entered the Share Exchange Agreement to acquire 100% of the issued and outstanding equity interests of Realbotix LLC in an all-stock transaction, and the combined company is expected to trade on Nasdaq following closing, subject to Onconetix shareholder approval, required regulatory approvals, and other closing conditions. A description of the Note is included in Onconetix's Current Report on Form 8-K filed with the SEC on September 14, 2026.
Onconetix IncOnconetix provides up to $5M bridge financing to its acquisition target Realbotix, with the advance reducing cash needed at closing.
Shanghai Henlius Biotech IncRealbotix receives up to $5M non-interest-bearing bridge financing from acquirer Onconetix ahead of the pending all-stock acquisition.